Immunotherapy — Therapeutic Area Intelligence | Humanexa Signals

RegulatoryAugust 6, 2026

FDA Accepts Supplement for KEYTRUDA QLEX (PEMBROLIZUMAB)

The FDA has accepted a supplemental application for KEYTRUDA QLEX, which includes pembrolizumab and berahyaluronidase alfa-PMPH.

ClinicalAugust 4, 2026

Phase II Trial of Ivonescimab in High-Risk Localized Clear Cell Renal Cell Cancer

A phase II trial is investigating the efficacy of ivonescimab as a pre-surgical treatment for high-risk localized clear cell renal cell cancer.

ClinicalAugust 1, 2026

Phase I Trial of Atezolizumab with Chemo for Relapsed/Refractory DLBCL

A pilot phase I trial is evaluating the combination of atezolizumab with rituximab, gemcitabine, and oxaliplatin in patients with relapsed/refractory transformed diffuse large B-cell lymphoma.

ClinicalAugust 1, 2026

Phase II Trial of Nivolumab and Cabozantinib for Mucosal Melanoma Recurrence Prevention

A phase II trial is underway to evaluate the efficacy of nivolumab alone or in combination with cabozantinib in preventing mucosal melanoma recurrence post-surgery.

ClinicalAugust 1, 2026

Trial of Cancer Lysate Vaccine with N-803 for PD-L1 Negative NSCLC Post-Surgery

A clinical trial is evaluating the combination of a cancer lysate vaccine and N-803 as adjuvant therapy for patients with PD-L1 negative non-small cell lung cancer (NSCLC) post-surgery.

ClinicalJuly 31, 2026

Phase II Trial of Nivolumab and Ipilimumab in Kidney Transplant Recipients with Metastatic Skin Cancer

A phase II trial is underway testing nivolumab and ipilimumab combined with sirolimus and prednisone in kidney transplant recipients with unresectable or metastatic skin cancer.

CompetitiveJuly 31, 2026

AI Transforming Immune Checkpoint Inhibitor Research: Key Trends Identified

A bibliometric analysis reveals a significant rise in AI applications in immune checkpoint inhibitor research, particularly in predicting treatment responses and managing adverse events.

ClinicalJuly 29, 2026

Nivolumab Added to Standard Treatment in Advanced Stomach/Esophageal Cancer Trial

The PARAMUNE trial is evaluating the efficacy of nivolumab combined with paclitaxel and ramucirumab in advanced gastric or esophageal adenocarcinoma.

ClinicalJuly 24, 2026

Pembrolizumab Trial for Small Cell Carcinoma of Ovary - Hypercalcemic Type

A clinical trial is investigating pembrolizumab as consolidation therapy for SCCOHT.

ClinicalJuly 23, 2026

Merck's MK-1045 Under Investigation for Non-Hodgkin Lymphoma Treatment

Merck is conducting a clinical study to evaluate the safety and efficacy of MK-1045 in patients with follicular lymphoma and diffuse large B-cell lymphoma.

ClinicalJuly 22, 2026

GSK Initiates First-Time-in-Human Study of Remzistotug for Advanced Solid Tumors

GlaxoSmithKline has launched a first-time-in-human study of remzistotug targeting advanced solid tumors.

RegulatoryJuly 21, 2026

FDA Accepts Supplement for IMFINZI (Durvalumab) by AstraZeneca

The FDA has accepted a supplemental application for IMFINZI (Durvalumab) from AstraZeneca.

RegulatoryJuly 19, 2026

FDA Accepts Supplement for ZYNYZ (Retifanlimab-Dlwr) by Incyte

The FDA has accepted a supplemental biologics license application for ZYNYZ (retifanlimab-Dlwr) from Incyte Corporation.

ClinicalJuly 19, 2026

Study Links Neoadjuvant Immunochemotherapy to Postoperative AHRF Risk in Thoracic Surgery

This multicentre cohort study investigates the association between neoadjuvant immunochemotherapy and the risk of postoperative acute hypoxemic respiratory failure in thoracic surgeries.

RegulatoryJuly 19, 2026

FDA Grants Priority Review for Tecentriq Hybreza Supplement Application

The FDA has granted priority review for the supplemental application of Tecentriq Hybreza, which combines atezolizumab with hyaluronidase.

ClinicalJuly 18, 2026

NCI Launches Biospecimen Study to Enhance Immunotherapy Research

The National Cancer Institute is conducting a study to collect biospecimens from cancer patients to improve treatment understanding.

ClinicalJuly 17, 2026

Dietary Butyrate Enhances Anti-PD-1 Efficacy in NSCLC via Gut Microbiome Modulation

Dietary supplementation with butyrate enhances anti-tumor activity and improves the efficacy of α PD-1 therapy in mice, linked to immune cell modulation.

RegulatoryJuly 15, 2026

FDA Accepts Supplemental Application for OPDIVO QVANTIG by Bristol-Myers Squibb

The FDA has accepted a supplemental application for OPDIVO QVANTIG, which includes nivolumab and hyaluronidase-NVHY.

ClinicalJuly 15, 2026

Phase II Trial of Nivolumab and Ipilimumab in dMMR Recurrent Endometrial Carcinoma

A phase II trial is testing the efficacy of nivolumab combined with ipilimumab versus nivolumab alone in patients with dMMR recurrent endometrial carcinoma.

ClinicalJuly 14, 2026

Study on Immune Function in BRCA1/2 Mutation Carriers Initiated

A clinical trial is evaluating immune function in healthy individuals with BRCA1/2 mutations.

ClinicalJuly 13, 2026

Challenges and Strategies in Nanomedicine-based Cancer Immunotherapy

Nanomedicine-based cancer immunotherapy faces significant translational barriers despite its preclinical promise.

ClinicalJuly 11, 2026

Study on Prebiotic Diet to Enhance Immunotherapy Response in Melanoma

A clinical trial is investigating the effects of a prebiotic food-enriched diet on the gut microbiome in melanoma patients undergoing immune checkpoint blockade therapy.

ClinicalJuly 10, 2026

Traditional Chinese Medicine Enhances Efficacy of Immune Checkpoint Inhibitors

Traditional Chinese medicine (TCM) can enhance the efficacy of immune checkpoint inhibitors (ICIs) and reduce their toxicity.

ClinicalJuly 9, 2026

Correlative Study on Epcoritamab in CLL and Richter Syndrome by NHLBI

A correlative study is being conducted to analyze the pharmacodynamic effects of epcoritamab in patients with chronic lymphocytic leukemia and Richter syndrome.

ClinicalJuly 7, 2026

Phase 2 Trial of Botensilimab + Balstilimab in Chemo-refractory Colorectal Cancer

A Phase 2 trial is investigating the efficacy and safety of botensilimab and balstilimab in patients with unresectable colorectal adenocarcinoma.

ClinicalJuly 5, 2026

Phase II/III Trial of Nivolumab and Ipilimumab for Advanced Melanoma Initiated

A Phase II/III trial is investigating the efficacy and safety of nivolumab and ipilimumab with or without sargramostim in patients with unresectable advanced melanoma.

ClinicalJuly 5, 2026

Phase 2 Trial of Pembrolizumab for Poor-Prognosis CUP Patients Initiated

A Phase 2 trial has been initiated to evaluate pembrolizumab in treatment-naïve patients with poor-prognosis carcinoma of unknown primary site.

ClinicalJuly 3, 2026

Phase II Trial of Nivolumab and Ipilimumab Before Surgery in Sarcomatoid Mesothelioma

A phase II trial is evaluating the safety and effectiveness of nivolumab and ipilimumab before surgery in patients with stage I-IIIa sarcomatoid mesothelioma.

RegulatoryJuly 1, 2026

FDA Approves Allogeneic T Cell Immunotherapy for Hematologic Malignancies

The FDA has approved a new allogeneic regulatory T cell-based immunotherapy for use in matched donor hematopoietic stem cell transplantation.

RegulatoryJuly 1, 2026

FDA Approves TREGZI for Chronic GVHD in Blood Cancer Patients

The FDA has approved TREGZI, the first Treg cell-based immunotherapy for chronic GVHD-free survival in blood cancer patients.

ClinicalJuly 1, 2026

LTβR as Novel Target for Cancer Immunotherapy: Mechanisms and Therapeutic Potential

LTβR plays a crucial role in tumor immune regulation and shows promise as a target for cancer immunotherapy, especially in combination with immune checkpoint inhibitors.

ClinicalJuly 1, 2026

Merck's MK-1045 Combined with Rituximab in Follicular Lymphoma Trial Launched

Merck is conducting a clinical trial to evaluate the safety and efficacy of MK-1045 in combination with rituximab for treating follicular lymphoma.

ClinicalJune 24, 2026

Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit

The INSIGHT trial is comparing durvalumab to standard observation in patients with early-stage non-small cell lung cancer post-surgery.

ClinicalJune 23, 2026

Phase III Trial of Cemiplimab in NSCLC Post-Surgery Shows Promise for Disease-Free Survival

A phase III trial is assessing the efficacy of cemiplimab in patients with surgically removed non-small cell lung cancer who have not received prior chemotherapy.

CompetitiveJune 22, 2026

Advances in Bacteria-Based Cancer Immunotherapy via Synthetic Biology

Synthetic biology techniques are enhancing the efficacy of bacteria-based cancer immunotherapies by improving tumor targeting and immune activation.

ClinicalJune 22, 2026

NCI Study on Immunotherapy Toxicities in Cancer Patients

The NCI is conducting a retrospective study to analyze immune-related adverse events (irAEs) associated with various immunotherapy trials.

ClinicalJune 22, 2026

Phase II Trial of Nivolumab and Ipilimumab for Rare Tumors

A phase II trial is investigating the efficacy of nivolumab and ipilimumab in patients with various rare tumors, with multiple cohorts based on tumor type.

ClinicalJune 21, 2026

Study Optimizes Immunotherapy for Pancreatic Adenocarcinoma Treatment

The study identifies opsonization and timing as critical factors influencing the efficacy of immunotherapy in pancreatic adenocarcinoma.

ClinicalJune 20, 2026

FCGR2B Targeting Enhances Anti-Tumor Activity of Macrophages in Melanoma

FCGR2B knockdown in tumor-associated macrophages enhances their anti-tumor capabilities by reducing M2 polarization and improving phagocytosis.

ClinicalJune 20, 2026

Study on COVID-19 Vaccine Safety in Cancer Immunotherapy Patients Launched

A retrospective study is being initiated to evaluate the safety of COVID-19 vaccines in patients undergoing immunotherapy for cancer.

ClinicalJune 19, 2026

Advancements in NK Cell-Based Immunotherapy for Cancer Treatment

NK cell therapies are advancing with promising safety profiles and clinical applicability, leveraging various innovative strategies.

ClinicalJune 18, 2026

Study on Treatment Patterns for Nivolumab in Community Oncology Settings

The study will analyze treatment patterns and safety events associated with nivolumab administration routes in cancer patients.

ClinicalJune 18, 2026

Nivolumab Phase III Trial for High Risk Stage II-IIIB Anal Cancer Initiated

A phase III trial is underway to evaluate the efficacy of nivolumab following combined modality therapy in high risk stage II-IIIB anal cancer patients.

ClinicalJune 18, 2026

Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer

A phase III trial is evaluating the efficacy of nivolumab following surgery and chemotherapy in patients with stage IB-IIIA non-small cell lung cancer.

ClinicalJune 17, 2026

Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer

The ALCHEMIST trial is evaluating the efficacy of adding pembrolizumab to standard chemotherapy in resected non-small cell lung cancer.

ClinicalJune 17, 2026

Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer

A phase III trial is evaluating the addition of durvalumab to standard chemotherapy in patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

CompetitiveJune 16, 2026

Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026

Five-year follow-up data from KEYNOTE-942 show the potential of intismeran autogene in combination with KEYTRUDA for high-risk melanoma. Additionally, KEYNOTE-522 results indicate a continued survival benefit for high-risk early-stage TNBC patients.

RegulatoryJune 16, 2026

Imfinzi Gains US Approval for Early Bladder Cancer with BCG Combination

Imfinzi has been approved in the US as the first immunotherapy combination for BCG-naïve, high-risk non-muscle-invasive bladder cancer, showing a 32% reduction in disease recurrence, progression, or death.

RegulatoryJune 11, 2026

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer

The FDA has accepted Roche's sBLA for Tecentriq plus chemotherapy in stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

RegulatoryJune 11, 2026

FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer

The FDA has accepted Roche's sBLA for Tecentriq in combination with chemotherapy for stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

Companies

Assets

Recent signals(50)

FDA Accepts Supplement for KEYTRUDA QLEX (PEMBROLIZUMAB)

Phase II Trial of Ivonescimab in High-Risk Localized Clear Cell Renal Cell Cancer

Phase I Trial of Atezolizumab with Chemo for Relapsed/Refractory DLBCL

Phase II Trial of Nivolumab and Cabozantinib for Mucosal Melanoma Recurrence Prevention

Trial of Cancer Lysate Vaccine with N-803 for PD-L1 Negative NSCLC Post-Surgery

Phase II Trial of Nivolumab and Ipilimumab in Kidney Transplant Recipients with Metastatic Skin Cancer

AI Transforming Immune Checkpoint Inhibitor Research: Key Trends Identified

Nivolumab Added to Standard Treatment in Advanced Stomach/Esophageal Cancer Trial

Pembrolizumab Trial for Small Cell Carcinoma of Ovary - Hypercalcemic Type

Merck's MK-1045 Under Investigation for Non-Hodgkin Lymphoma Treatment

GSK Initiates First-Time-in-Human Study of Remzistotug for Advanced Solid Tumors

FDA Accepts Supplement for IMFINZI (Durvalumab) by AstraZeneca

FDA Accepts Supplement for ZYNYZ (Retifanlimab-Dlwr) by Incyte

Study Links Neoadjuvant Immunochemotherapy to Postoperative AHRF Risk in Thoracic Surgery

FDA Grants Priority Review for Tecentriq Hybreza Supplement Application

NCI Launches Biospecimen Study to Enhance Immunotherapy Research

Dietary Butyrate Enhances Anti-PD-1 Efficacy in NSCLC via Gut Microbiome Modulation

FDA Accepts Supplemental Application for OPDIVO QVANTIG by Bristol-Myers Squibb

Phase II Trial of Nivolumab and Ipilimumab in dMMR Recurrent Endometrial Carcinoma

Study on Immune Function in BRCA1/2 Mutation Carriers Initiated

Challenges and Strategies in Nanomedicine-based Cancer Immunotherapy

Study on Prebiotic Diet to Enhance Immunotherapy Response in Melanoma

Traditional Chinese Medicine Enhances Efficacy of Immune Checkpoint Inhibitors

Correlative Study on Epcoritamab in CLL and Richter Syndrome by NHLBI

Phase 2 Trial of Botensilimab + Balstilimab in Chemo-refractory Colorectal Cancer

Phase II/III Trial of Nivolumab and Ipilimumab for Advanced Melanoma Initiated

Phase 2 Trial of Pembrolizumab for Poor-Prognosis CUP Patients Initiated

Phase II Trial of Nivolumab and Ipilimumab Before Surgery in Sarcomatoid Mesothelioma

FDA Approves Allogeneic T Cell Immunotherapy for Hematologic Malignancies

FDA Approves TREGZI for Chronic GVHD in Blood Cancer Patients

LTβR as Novel Target for Cancer Immunotherapy: Mechanisms and Therapeutic Potential

Merck's MK-1045 Combined with Rituximab in Follicular Lymphoma Trial Launched

Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit

Phase III Trial of Cemiplimab in NSCLC Post-Surgery Shows Promise for Disease-Free Survival

Advances in Bacteria-Based Cancer Immunotherapy via Synthetic Biology

NCI Study on Immunotherapy Toxicities in Cancer Patients

Phase II Trial of Nivolumab and Ipilimumab for Rare Tumors

Study Optimizes Immunotherapy for Pancreatic Adenocarcinoma Treatment

FCGR2B Targeting Enhances Anti-Tumor Activity of Macrophages in Melanoma

Study on COVID-19 Vaccine Safety in Cancer Immunotherapy Patients Launched

Advancements in NK Cell-Based Immunotherapy for Cancer Treatment

Study on Treatment Patterns for Nivolumab in Community Oncology Settings

Nivolumab Phase III Trial for High Risk Stage II-IIIB Anal Cancer Initiated

Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer

Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer

Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer

Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026

Imfinzi Gains US Approval for Early Bladder Cancer with BCG Combination

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer

FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer

Upcoming catalysts

Indications

Get signals before the market moves